University Hospitals Plymouth NHS Trust

Plymouth PL6 8DH

4 studies enrolling now · 20 studies all time

What they study most

Acute Leukemia, Alcohol Associated Hepatitis, Atrial Fibrillation, Bleeding, COVID-19, Chronic Lymphocytic Leukemia (CLL), Chronic Spontaneous Urticaria, Coronavirus Infection, Diffuse Large B Cell Lymphoma (DLBCL), Follicular Lymphoma (FL), Huntington Disease, Huntington's Disease

Studies at this site

• A Phase 1/2 Study of Bleximenib in Participants With Acute Leukemia (cAMeLot-1) — Recruiting now
• A Study of NX-5948 in Adults With Relapsed/Refractory B-cell Malignancies — Recruiting now
• Anticoagulation for New-Onset Post-Operative Atrial Fibrillation After CABG — Recruiting now
• HDClarity: a Multi-site Cerebrospinal Fluid Collection Initiative to Facilitate Therapeutic Development for Huntington's Disease — Recruiting now
• Compassionate Use for BIA 28-6156 in Patients With Parkinson's Disease (PD) Who Have a Pathogenic Variant in the GBA1 Gene (GBA-PD) and Completed the ACTIVATE Study — NO_LONGER_AVAILABLE
• Efficacy and Safety of M281 in Adults With Warm Autoimmune Hemolytic Anemia — Running, not enrolling
• A Study Comparing Talquetamab Plus Pomalidomide, Talquetamab Plus Teclistamab, and Elotuzumab, Pomalidomide, and Dexamethasone or Pomalidomide, Bortezomib, and Dexamethasone in Participants With Relapsed or Refractory Myeloma Who Have Received an Anti-CD38 Antibody and Lenalidomide — Running, not enrolling
• A Study of Teclistamab in Combination With Daratumumab Subcutaneously (SC) (Tec-Dara) Versus Daratumumab SC, Pomalidomide, and Dexamethasone (DPd) or Daratumumab SC, Bortezomib, and Dexamethasone (DVd) in Participants With Relapsed or Refractory Multiple Myeloma — Running, not enrolling
• A Study Comparing Talquetamab in Combination With Daratumumab or in Combination With Daratumumab and Pomalidomide Versus Daratumumab in Combination With Pomalidomide and Dexamethasone in Participants With Multiple Myeloma That Returns After Treatment or is Resistant to Treatment — Running, not enrolling
• Efficacy, Safety, Tolerability, Pharmacodynamics, and Pharmacokinetics of BIA 28-6156 in GBA-PD — Running, not enrolling
• FXR Effect on Severe Alcohol-Associated Hepatitis (FRESH) Study — Stopped early
• A Study of mRNA-1283 Injection Compared With mRNA-1273 Injection in Participants ≥12 Years of Age to Prevent COVID-19 — Completed
• To Evaluate the Efficacy of CVN424 in Parkinson's Disease Participants With Motor Complications — Running, not enrolling
• A Phase 3 Study of Barzolvolimab in Participants With Chronic Spontaneous Urticaria (CSU) — Running, not enrolling
• A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ≥50 Years of Age — Completed
• Efficacy, Safety and Tolerability Study of ND0612 vs. Oral Immediate Release Levodopa/Carbidopa (IR-LD/CD) in Subjects With Parkinson's Disease Experiencing Motor Fluctuations — Running, not enrolling
• Study to Evaluate the Efficacy and Safety of Camidanlumab Tesirine (ADCT-301) in Patients With Relapsed or Refractory Hodgkin Lymphoma — Completed
• (PROSPECTOR) Screening Study Evaluating the Prevalence of the KIT D816V Mutation in Patients With Systemic Mast Cell Activation — Completed
• Evaluation of Activity and Safety of Oral Selinexor in Participants With Severe COVID-19 Infection — Completed
• Development of Assessments for Later Stage HD — Status unconfirmed